 At Johns Hopkins, I'm Elizabeth Tracy. If you have type 2 diabetes, what are the best medicines to manage it? A new meta-analysis looks at aggregated data from a number of studies and comes out in favor of the newer classes of drugs. Rita Kalyani, a diabetes expert at Johns Hopkins, describes the results. They found that as a class, SGLT2 inhibitors in GLP-1 receptor agonists reduced all-cause mortality and major adverse cardiovascular events.